Related Experiment Video
Updated: Jun 17, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review
Oluwaremilekun Tolu-Akinnawo1, David N Ray2, Tiwalade Awosanya3
1Internal Medicine, Meharry Medical College, Nashville, USA.
Insights
New device-based treatments are emerging to manage uncontrolled hypertension, offering alternatives to medication. These innovative approaches target the autonomic nervous system and other pathways to lower blood pressure effectively.
Area of Science:
- Cardiovascular Medicine
- Medical Devices
- Interventional Cardiology
Background:
- Hypertension is a leading modifiable risk factor for cardiovascular mortality, affecting 1.3 billion people globally.
- Despite available medications, a significant portion of hypertensive patients remain uncontrolled.
- New therapeutic strategies are needed to manage resistant hypertension and its complications.
Purpose of the Study:
- To review current and emerging device-based interventions for arterial hypertension management.
- To discuss recently approved and investigational devices modulating the autonomic nervous system and other physiological pathways.
Main Methods:
- Review of recently FDA-approved devices, including renal denervation (RDN).
- Discussion of investigational device-based therapies in clinical trials.
- Categorization of devices by mechanism of action (e.g., neuromodulation, chemoreceptor modulation).
Main Results:
- Two renal denervation (RDN) devices received FDA approval in November 2023.
- Investigational devices show promising results in clinical testing for blood pressure reduction.
- Various device classes target different physiological mechanisms, including autonomic nervous system activity.
Conclusions:
- Device-based therapies represent a growing area for interventional hypertension management.
- Emerging technologies offer new hope for patients with uncontrolled blood pressure.
- Personalized approaches considering pathophysiology and procedural risks are crucial for device selection.
Abstract:
Hypertension is the most prevalent modifiable risk factor associated with cardiovascular mortality. The World Health Organization (WHO) estimates that hypertension directly or indirectly causes the death of at least nine million people globally every year. The number of people living with hypertension (blood pressure (BP) of ≥140 mmHg systolic or ≥90 mmHg diastolic or on medication) doubled between 1990 and 2019, from 650 million to 1.3 billion. Despite a plethora of antihypertensive drugs widely available, a sizable part of the antihypertensive population stays uncontrolled. The unmet need of controlling BP in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. Several device-based approaches have been introduced to lower BP, and most of these strategies aim to modulate autonomic nervous system activity. Importantly, when considering a device-based treatment, each patient's underlying pathophysiology is considered, and the procedural risks are weighed against the cardiovascular risk attributed to the elevated BP. In November 2023, the FDA approved two renal denervation (RDN) devices. This manuscript discusses current interventional devices and procedures recently approved (RDN) and others in the clinical testing stage for arterial hypertension intervention or management. As we list below, all others have shown promising results and are being evaluated on a larger clinical trial. The new device-based classes are as follows: catheter-based RDN, baroreflex amplification, arteriovenous (AV) malformation, carotid body (CB) ablation, pacemaker-based cardiac neuromodulation, electro-acupuncture, and deep brain stimulation. Baroreflex amplification uses peripheral neuromodulation, while AV malformation leverages AV anastomosis. CB ablation modulates chemoreceptors, and pacemaker-based neuromodulation adjusts atrioventricular intervals. Electro-acupuncture proves potential, and deep brain stimulation offers central nervous system intervention.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug Therapy
Antianxiety Medications
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Angiotensin II Receptor Blockers

